Head-to-head · WeighScore
Maves vs ShedRx
The verdict
ShedRx takes it — 87/100 to 71.8/100.
ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The widest formulation spread on the board — injection, drops, lozenges and a daily oral pill, plus a real brand Zepbound lane.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Maves | ShedRx |
|---|---|---|
| WeighScore | 71.8/100 | 87/100 |
| Grade | C | B+ |
| Scorecard rank | #89 | #3 |
| Semaglutide | $99/mo (starting dose, first-month rate, compounded) | $199/mo |
| Tirzepatide | Not disclosed | $299/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Graded #3 · B+
Strengths
- Four GLP-1 routes — injection, liquid drops, lozenges and an oral daily pill
- Brand Zepbound and Wegovy available beside the compounded line
- Health coaching included with membership, plus a published 120-day weight-loss guarantee
Where it loses points
- The advertised "as low as $239" tirzepatide rate requires a twelve-month commitment — month-to-month is $299
- Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
- The dispensing compounding pharmacy is not publicly named
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.